AHA on July 21 submitted comments on how Congress can ensure that the 340B program continues to benefit patients and communities, while acting to prevent any cuts to the program that would jeopardize patient access to care. Responding to a bipartisan request by senators for input, AHA strongly urged that the Health Resources and Services Administration finalize its Administrative Dispute Resolution rule for the 340B program and explicitly state that the ADR process is an available forum for affected 340B hospitals to seek redress from restrictions targeted to community and specialty pharmacies. AHA also recommended that Congress require HRSA to increase its annual audits of drug companies in the 340B program, which average six per year compared with over 200 per year for 340B covered entities, and give hospitals and other covered entities the ability to audit drug manufacturers.

Related News Articles

Headline
Following last year’s unanimous Supreme Court decision in favor of the AHA and others, the Department of Health and Human Services Nov. 2 issued a final…
News
The Health Resources and Services Administration will require hospitals in the 340B Drug Pricing Program to register their off-site outpatient departments,…
Perspective
With only 11 days that the House and Senate are in session together before the fiscal year concludes, much of the attention in Washington is on how Congress…
Headline
The Centers for Medicare & Medicaid Services has extended to Sept. 11 the deadline to submit comments on its proposed remedy for the unlawful payment…
Headline
AHA urged the House Energy and Commerce Committee to consider including in its draft legislation to address drug shortages legislative proposals that would…
Headline
The AHA filed its comment letter on the Department of Health and Human Services’ proposed remedy for the unlawful payment cuts to certain hospitals that…